NUS spinout MediSix has obtained $20m from investors including Osage University Partners to commercialise research into leukaemia and lymphoma treatments.
MediSix Therapeutics, a Singapore-based cell therapy spinout from National University of Singapore (NUS), closed a $20m series A round yesterday that featured spinout-focused investment firm Osage University Partners.
The round was led Lightstone Ventures and also included Singaporean state-owned investment firm Temasek.
MediSix is developing an immunotherapy that targets lymphoma and leukaemia. It is also commercialising a cell engineering platform that is expected to enable applications beyond T-cell malignancies.
The company is based on research by founder Dario Campana, professor in the Department of Paediatrics in the Yong Loo Lin School of Medicine at NUS.
The funding will allow MediSix to hire additional staff, advance product development and launch pre-clinical studies.
MediSix previously obtained an undisclosed sum from Lightstone Singapore, a fund managed by Lightstone Ventures, according to the latest press release.
Campana said: “We are delighted to have completed this initial financing with a strong group of early investors.
“This financing is a testament to MediSix’ novel approach to developing treatments that target T-cell malignancies, as well as our investors’ confidence in our ability to quickly bring these potentially life-saving therapies to patients affected with these aggressive forms of cancer.”
